ArticleAnnals of translational medicine2024
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.
Bruno de Paula et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.